Fortress Biotech, Inc. (FBIO) - Form 8-K Summary
Business Context and Reporting Period
On December 12, 2025, Fortress Biotech, Inc. filed a Current Report on Form 8-K regarding the entry into a material definitive agreement. The Company, incorporated in Delaware and trading on the Nasdaq Capital Market, amended its existing Credit Agreement with Oaktree Fund Administration, LLC and its lenders.
Key Financial Metrics and Debt Structure
- Outstanding Debt: Approximately $29.5 million as of the report date.
- Total Loan Capacity: Initial borrowing of $35.0 million with eligibility to draw an additional $15.0 million subject to lender consent.
- Maturity Date: Extended from July 25, 2027, to June 30, 2028.
- Equity Issuance: Granted warrants to purchase up to 600,000 shares of Common Stock at an exercise price of $2.62 per share.
- Warrant Terms: Immediately exercisable, expiring July 25, 2031, with net exercise options and anti-dilution protections.
Material Changes and Covenant Modifications
The Amendment introduced significant changes to the repayment schedule and financial covenants:
- Repayment Schedule: Principal repayments are now structured as follows based on the outstanding balance as of September 30, 2027:
- 12.5% due September 30, 2027
- 12.5% due December 31, 2027
- 37.5% due March 31, 2028
- 37.5% due June 30, 2028 (Maturity)
- Financial Covenant (Minimum Net Sales Test): The covenant requires Journey Medical Corporation (a controlled subsidiary) to meet specific trailing twelve-month product net sales targets:
- $60.0 million by December 31, 2025
- $65.0 million by March 31, 2026
- $70.0 million by June 30, 2026
- $75.0 million by September 30, 2026
- $80.0 million by December 31, 2026 and thereafter
- Covenant Exemption: The Minimum Net Sales Test does not apply if the outstanding principal balance is $10.0 million or less.
Outlook, Risks, and Contingencies
Failure to meet the Minimum Net Sales Test constitutes an event of default, subject to certain cure rights. The filing notes that the Warrants are issued under an exemption from registration under Section 4(a)(2) of the Securities Act. The Company agreed to file a registration statement for the resale of shares issuable upon warrant exercise. The filing text does not provide specific revenue, profit, or cash flow figures for the current period, nor does it contain explicit forward-looking guidance beyond the covenant targets.
Key Facts for Investor Verification
- Verify the current outstanding principal balance of the Loan to determine if the Minimum Net Sales Test is currently active (threshold is $10.0 million).
- Confirm Journey Medical Corporation's trailing twelve-month product net sales against the $60.0 million target for the quarter ending December 31, 2025.
- Monitor the Company's cash position to ensure ability to meet the new quarterly principal repayment schedule starting September 30, 2027.
- Review the impact of the 600,000 warrant issuances on potential future dilution, noting the anti-dilution provisions tied to share prices below $2.62.